我是 LongbridgeAI，我可以总结文章信息。Kahn Swick & Foti, LLC 正在调查 Supernus Pharmaceuticals 拟出售给 Indivior Pharmaceuticals 的事宜。该公司正在审查每股 Supernus 以 1.5401 股 Indivior 交换的比例是否充分评估了该公司的价值，以及交易过程是否公平。对潜在低估表示担忧的股东被鼓励联系该律师事务所以讨论他们的法律权利
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at (833) 538-3612, or visit https://www.ksfcounsel.com/cases/nasdaqgm-supn/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn
KSF Managing Partner Lewis S. Kahn
lewis.kahn@ksfcounsel.com
(833) 538-3612
Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163
View source version on businesswire.com: https://www.businesswire.com/news/home/20260807988617/en/